Φορτώνει......
HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
BACKGROUND: TTFields plus TMZ treatment significantly increased five-year overall survival results compared to TMZ alone in all patients in the EF-14 trial, with the subgroup of patients age 65 and older showing the greatest survival benefit (hazard ratio 0.51 [CI 0.33–0.77]). This is the first repo...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Neuro Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Oxford University Press
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217146/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.486 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|